Clinical trials studying GLP-1 medications for weight management and cardiovascular outcomes also measured cholesterol and other lipid markers as secondary outcomes — not as the primary focus of those studies. What those trials reported, what they did not find, and why the picture is more complex than a simple yes-or-no answer is the focus of this page. Whether any of those findings apply to your individual results is a question only the provider who knows your complete health history can answer.
What Is a Lipid Panel — and Why Does It Come Up on GLP-1?
When someone starts a GLP-1 medication, their provider will typically order routine blood work at follow-up visits. One standard part of that blood work is a lipid panel — a test that measures different fats circulating in the bloodstream.
According to the National Heart, Lung, and Blood Institute (NHLBI), a lipid panel typically includes total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. LDL is often called “bad” cholesterol because higher levels are linked to cardiovascular risk, while HDL is described as “good” cholesterol. Triglycerides are a separate type of blood fat that providers also monitor as part of cardiovascular health assessment. More information on what these markers mean is available from the NHLBI’s blood cholesterol overview.
Lipid panels come up in GLP-1 conversations for two reasons. First, many people starting these medications have underlying conditions — such as obesity or type 2 diabetes — that are often associated with lipid imbalances. Second, several large clinical trials studying GLP-1 medications included lipid panel measurements as part of their data collection. That means there is now a body of data about what happened to lipid markers in those trial populations, even though studying cholesterol was not the main purpose of those trials.
GLP-1 medications are approved for specific uses — primarily weight management and, in some cases, reducing cardiovascular risk in people with established heart disease. They are not approved or prescribed as a treatment for high cholesterol. That distinction matters when reading what the research actually says.
If you are already monitoring other metabolic markers such as blood glucose alongside your GLP-1 treatment, see our page on recording metabolic lab values during GLP-1 treatment.
Tracking Over Time
Tracking your lipid panel values over time gives your provider a clearer picture of trends. The GLP-1 Journal tracker lets you log your blood work results alongside your other health data — stored privately on your device.
What Large Clinical Trials Have Reported About Lipid Markers
Two large, rigorous clinical trials involving semaglutide measured lipid panel markers as part of their data collection. Understanding what these trials were actually designed to study helps put the lipid findings in the right context.
The STEP 1 trial (Wilding et al., 2021), published in the New England Journal of Medicine, studied semaglutide as a weight management treatment in adults with overweight or obesity who did not have type 2 diabetes. It was a weight management trial — lipid markers were among several measurements collected as secondary outcomes alongside the primary weight loss data.
The SELECT trial (Lincoff et al., 2023), also published in the New England Journal of Medicine, studied semaglutide in adults with obesity and established cardiovascular disease. Its primary goal was to assess whether the medication reduced the rate of major cardiovascular events in that population. Lipid measurements were included as part of the broader cardiovascular data collection, not as the trial’s main question.
A 2024 meta-analysis by Rivera et al., published in Current Medical Research and Opinion, pooled data from multiple placebo-controlled randomized trials of GLP-1 receptor agonists and analyzed specifically what those trials found about lipid markers across the class of medications.
Total Cholesterol and LDL Cholesterol
The Rivera et al. (2024) meta-analysis found that across the trials analyzed, GLP-1 medications were associated with modest reductions in LDL cholesterol and total cholesterol. The analysis found this pattern appeared to hold independent of the degree of weight change within that dataset — a finding the authors described as modest and one that applies to the trial populations studied, not to any individual.
Across individual trials within that analysis, the size of any association varied. What the meta-analysis reports is a directional pattern at the population level in those specific study groups, using statistical methods to account for weight change.
Triglycerides
Among the lipid markers measured in GLP-1 clinical trials, triglycerides showed some of the more consistent patterns. Several analyses found reductions in triglyceride levels among trial participants. The Rivera et al. (2024) meta-analysis included triglycerides in its review, though consistency of findings varied across different study designs and patient populations within the pooled data.
As with other lipid markers, these observations reflect what was measured in clinical trial groups. They do not indicate what will happen in any given individual.
HDL Cholesterol
HDL cholesterol — often called “good” cholesterol — showed the least consistent pattern across studies. The Rivera et al. (2024) meta-analysis found no statistically significant effect on HDL levels across the trials analyzed as a group. Some individual studies within the literature showed small changes in HDL, but the overall picture across published research is less clear for this marker than for LDL or triglycerides.
| Marker | What trials measured | Pattern seen across studies | What this means for individuals |
|---|---|---|---|
| LDL cholesterol | Secondary outcome in weight management and cardiovascular trials | Some analyses found modest reductions; size and consistency varied across studies and populations | Requires individual monitoring with your provider; trial averages do not predict individual results |
| Triglycerides | Secondary outcome | Several analyses found reductions; among the more consistent findings across the literature | Still a secondary finding in trials not designed to study this specifically; individual results vary |
| HDL cholesterol | Secondary outcome | Largely unchanged in most analyses; small and inconsistent changes in some individual studies | No clear consistent pattern at population level; discuss your specific results with your provider |
| Total cholesterol | Secondary outcome | Some modest reductions noted in analyses, including the Rivera et al. (2024) meta-analysis | Interpret in clinical context; part of the broader picture your provider reviews |
Context
Clinical trial data reflects group averages in specific study populations. These findings do not describe what will happen to your individual lipid panel. Your provider is the right person to interpret your specific results in the context of your health history.
Why the Evidence Is More Complex Than It Looks
Reading that GLP-1 medications may be associated with cholesterol changes can be easy to misinterpret without understanding what that statement actually rests on.
One significant challenge in reading the lipid data from GLP-1 trials is that many participants also lost meaningful amounts of body weight during these studies. Weight loss itself is known to affect lipid markers — it can reduce triglycerides, modestly affect LDL, and in some cases influence HDL. This makes it difficult to separate how much of any observed lipid change comes from the medication directly versus from the weight loss that often accompanies treatment.
The Rivera et al. (2024) meta-analysis attempted to account for this by using meta-regression — a statistical method to separate the weight-change effect from the medication effect within the data. Their analysis found that some of the LDL and total cholesterol pattern remained even after accounting for weight in that way. However, fully separating direct drug effects from weight-related effects remains a methodological challenge across the literature, and this remains an active area of investigation.
The patient populations in these trials were also not uniform. STEP 1 focused on people with overweight or obesity without type 2 diabetes. SELECT focused on people with obesity and existing cardiovascular disease. Rivera et al. (2024) pooled data from multiple trials involving different GLP-1 receptor agonists as a class, across varied populations. Different baseline lipid profiles and different health conditions across these groups contribute to why findings vary.
None of these trials were designed with cholesterol treatment as their primary goal. That context is important for anyone wondering whether their GLP-1 medication will specifically help or change their cholesterol numbers.
What the Research Has Not Established
Despite the growing body of data, there are important limits to what has been established.
Individual prediction is not possible from trial data. Even when a study finds that, on average, a group of trial participants saw certain lipid changes, this does not mean that any given person on a GLP-1 medication will see the same. Individual variation is substantial, and many factors — including genetics, diet, activity level, other medications, and baseline health conditions — influence a person’s lipid panel in ways that trial averages cannot capture.
GLP-1 medications are not approved for the treatment of high cholesterol. They are not a substitute for medications that are specifically prescribed for that purpose. The clinical trials that generated these data were designed to study weight management and cardiovascular outcomes — not to evaluate these medications as treatments for lipid conditions. Treating high cholesterol remains a separate clinical question that requires separate clinical decisions.
Important
Do not stop or change any cholesterol medication based on this information or on expectations about what a GLP-1 medication might do for your lipid numbers. Any decision about your lipid-related medications should be made with your prescribing provider, who can review your complete medical history and recent lab work.
What the research has suggested — and what it has not — is a meaningful distinction. Some lipid markers in some trial populations showed modest associations with GLP-1 medications. Whether that is relevant to a specific person, in a specific clinical situation, with a specific health history, requires a conversation with a qualified provider who can interpret that person’s actual results.
How to Track Your Lipid Panel Results Over Time
If your provider is ordering lipid panels as part of routine monitoring while you are on a GLP-1 medication, keeping a record of your results over time can be useful when you come in for appointments.
A single lipid panel reading may reflect many variables on that particular day — when you last ate, how hydrated you were, activity in the days before the test, or even lab-to-lab variation. Tracking results across multiple appointments gives your provider a trend line rather than a single snapshot, which tends to be more useful clinically.
When you receive lipid panel results, a few things are worth noting alongside the numbers:
- When was the test taken, and was it fasted or non-fasted?
- What other health changes happened since your last panel — changes in weight, diet, activity, or medications?
- How long have you been on your current GLP-1 treatment?
The GLP-1 Side-Effect and Progress Tracker lets you log your blood work results — including lipid panel values — alongside your other health entries such as side effects, energy levels, and meal notes. Everything is stored locally on your device. When you come in for a provider appointment, you can review this record together to look at patterns over time.
For guidance on preparing a summary for your provider that includes both lab results and symptom patterns, see how to prepare a progress log for provider visits.
Other metabolic markers your provider may track alongside your lipid panel — such as liver enzymes or blood glucose — are discussed in our page on GLP-1 and liver health markers.
Questions to Bring to Your Provider About Your Cholesterol Numbers
One of the most practical things someone on a GLP-1 medication can do is arrive at provider appointments with specific questions about their lipid results. Providers see many patients and may not always know which numbers you have been thinking about between visits. Having prepared questions can help make those conversations more useful.
Here are six questions that may help guide those conversations:
- “My lipid panel from [date] showed these results — is anything in these numbers worth paying attention to at my current stage of treatment, or does the picture look typical for someone in my situation?”
- “Should I expect my cholesterol numbers to change while I’m on this medication, or is treating cholesterol not something this treatment is designed to do?”
- “Are there other factors right now — my recent weight change, changes in my diet, or other medications I’m taking — that might be affecting what my lipid panel is showing?”
- “How often do you recommend I get a lipid panel while I’m on this treatment, and is there a point where the frequency might change?”
- “If my LDL or triglycerides look different at my next check, what would be the threshold where you might recommend a change in how we’re managing my cardiovascular health overall?”
- “Is there anything in my recent lipid results that I should keep a closer eye on between now and our next appointment?”
These questions are not meant to replace clinical judgment — they are designed to help open a conversation with the provider who knows your complete history and is best positioned to interpret your specific numbers.
For help preparing a broader record to bring to provider visits — including side effects, progress notes, and lab values — see how to organize a comprehensive visit record for your provider.